phospholipase/neoplasms

BACKGROUND OF THE INVENTION Mammalian response to injury or inflammation is a complex series of events. Shortly after an event which elicits an inflammatory cascade, the release of eicosanoids is initiated. The release of eicosanoids is mediated by the activation of Phospholipase A.sub.2 (PLA.sub.2)

BACKGROUND OF THE INVENTION Phospholipases C (EC 3.1.4.3) are a family of enzymes which hydrolyze the sn-3 phosphodiester bond in membrane phospholipids producing diacylglycerol and a phosphorylated polar head group. Mammalian phospholipase C (PLC) enzymes exhibit specificity for the polar head

BACKGROUND OF THE INVENTION 1. Field of the Invention This invention is directed to methods for preventing the emergence of multidrug resistance in tumor cells during cancer chemotherapy. In particular, it relates to the use of inhibitors of particular pathways of signal transduction to prevent the

FIELD OF THE INVENTION The present invention pertains to a novel 18-residue dimerized peptide designated PIP [59-67] dimer, having dual inhibitory activity against secretory phospholipase A2 (sPLA2) and matrix metalloproteinases (MMPs). This novel peptide inhibitor of the invention not only inhibits

The present invention relates to methods and compositions that provide for the diagnosis and treatment of prostatic intraepithelial neoplasia. A particular aspect of the invention relates to methods and compositions containing compounds which inhibit phospholipase A.sub.2, particularly those that

BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates generally to the fields of radiation biology and cell biology. More particularly, it concerns the attenuation of the effect of ionizing radiation induced activation of tumor necrosis factor by inhibitors of

BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates generally to the fields of radiation biology and cell biology. More particularly, it concerns the attenuation of the effect of ionizing radiation induced activation of tumor necrosis factor by inhibitors of

TECHNICAL FIELD This invention is in the field of molecular biology and particularly relates to nucleic acid sequences that encode novel phospholipases. BACKGROUND The mechanism by which specificity of physiological responses are conferred by a limited number of signal transducing substances,

TECHNICAL FIELD This invention is in the field of molecular biology and particularly relates to nucleic acid sequences that encode novel phospholipases. BACKGROUND The mechanism by which specificity of physiological responses are conferred by a limited number of signal transducing substances,

CROSS REFERENCE TO RELATED APPLICATIONS The present application is a national phase entry under 35 U.S.C. .sctn.371 of International Application No. PCT/JP2006/320611, filed Oct. 17, 2006, published in Japanese, which claims benefit of Japanese Patent Application No. 2005-321108, filed Nov. 4, 2005.

FIELD OF THE INVENTION This invention relates to treatment of mammals, including humans suffering from cancerous tumors, particularly malignant gliomas and other tumors of the central nervous system, and to tumor models for evaluating effectiveness of such treatments. BACKGROUND OF THE INVENTION In

The present invention relates to methods and compositions that prevent or inhibit metastases of cancers of epithelial cell origin, especially human prostate cancers. A particular aspect of the invention relates to methods and compositions that inhibit arachidonic acid release in cells of these

The present invention relates to methods and compositions that provide for the diagnosis and treatment of prostatic intraepithelial neoplasia. A particular aspect of the invention relates to methods and compositions containing compounds which inhibit phospholipase A.sub.2, particularly those that

The present invention relates to methods and compositions that provide for the diagnosis and treatment of prostatic intraepithelial neoplasia. A particular aspect of the invention relates to methods and compositions containing compounds which inhibit phospholipase A.sub.2, particularly those that

BACKGROUND OF THE INVENTION 1. Field of the Invention The present application concerns medical sciences and more particularly detection and treatment of human cancers, especially breast cancer. 2. Description of Related Art Membrane associated heparan sulfate proteoglycans (HSPGs) are thought to